News, Analysis, Trends, Management Innovations for
Clinical Laboratories and Pathology Groups

Hosted by Robert Michel

News, Analysis, Trends, Management Innovations for
Clinical Laboratories and Pathology Groups

Hosted by Robert Michel
Sign In

Debut of ixlayer on Inc. 5000 List of Fastest Growing Businesses for 2023 Indicates a Dynamic Clinical Laboratory Test ‘Middleman’ Sector

Growth of the middleman company is a sign of increased credibility and acceptance among its client organizations

There’s a new category of player in the clinical laboratory testing industry. It is the “middleman” company. One high-profile example of a middleman company in diagnostics is the company ixlayer of San Francisco, which has a novel plan for growth.

The software developer provides cloud-based diagnostic testing platforms to retailers, health plans, and biopharma companies. Medical laboratory tests are not processed by ixlayer, however, but are instead sent to independent CLIA-certified clinical labs for completion and results reporting.

Thus, ixlayer acts as a third-party “middleman” in the lab testing chain.

Ixlayer recently debuted as number 1,418 on the 2023 Inc. 5000 list of fastest-growing private companies in the US, according to a company news release. Might this signal a dynamic and expanding clinical laboratory middleman sector?

There are a number of other established middleman companies doing this on the web as well, including:

Produced by Inc. Business Media, the Inc. 5000 list is based on data analysis of the fastest growing private businesses in the US. Ixlayer reportedly grew its 2023 revenue 100% year-over-year. 

Pouria Sanae

“To be selected for the Inc. 5000 list is an honor that validates the value we deliver while enabling greater access to care for all,” said Pouria Sanae (above), co-founder and CEO of ixlayer. “We’ve developed a platform that powers millions of diagnostic tests each year and serves as the backbone of thousands of health testing programs for trusted health brands, healthcare delivery organizations, payers, and life sciences companies. I’m excited about the future as we redefine and simplify the diagnostic laboratory testing ecosystem.” (Photo copyright: ixlayer.)

Ixlayer Works with Retailers, Insurers, Biopharma, and Clinical Labs

Ixlayer “facilitates” tests by working with industry partners and clinical laboratories, Managed Healthcare Executive explained.

One such relationship is with retailer CVS, Fierce Healthcare reported. Ixlayer provides the cloud-based diagnostics platform, at-home sample collection kits, and coordination of testing services for some of the pharmacy company’s at-home testing products. They include:

“With nearly 70% of medical decisions dependent on lab testing, regular diagnostic testing is a cornerstone of improving health and wellness,” Pouria Sanae, co-founder and CEO of ixlayer, told Drug Store News. “At-home testing enables people to proactively take control of their health, on their own schedule, in the privacy of their own home and on a regular basis. Our mission of creating a healthier world through more accessible, affordable, and easy health testing requires systemic changes and buy-in from key stakeholders and partners.”

Ixlayer directs specimens to independent labs that perform the tests and report results to consumers via an online portal.

“Founded in 2018, ixlayer initially focused on remote lab testing for Alzheimer’s disease patients. The company now offers thousands of white-labeled, at-home, and onsite health tests ranging from women’s wellness to sexually transmitted diseases and chronic condition management,” the news release notes.

“We’re thinking of it more from the perspective of: How do we infiltrate this infrastructure into our whole healthcare ecosystem? How do we let traditional providers run their programs the way they want to?” Alecia Pritchett, ixlayer Chief Growth Officer, told Managed Healthcare Executive.

Ixlayer “is not a lab,” Managed Healthcare Executive explained. “It describes itself as a platform. Instead of performing its own lab tests, it connects providers and retailers to accredited laboratory partners. Instead of sending out its own team of phlebotomists to collect blood samples, the company coordinates with mobile phlebotomy firms.”

“This comprehensive data visualization solution provides a more insightful analysis of testing performance data, empowering health plans, retailers, and biopharma organizations to monitor and manage progress in real-time effectively. With this actionable intelligence, decision-makers can focus on addressing gaps in care, accelerating access to critical drug studies, and promoting greater health equity to improve clinical and quality outcomes and economics across the healthcare ecosystem,” said David Yu, Chief Product Officer at ixlayer, in a news release.

Any Lab Test Now Also Makes Inc.’s 5000 List

Also making the 2023 Inc. 5000 list is Any Lab Test Now, an Alpharetta, Ga.-headquartered laboratory franchise that was founded in 2007. Any Lab Test Now is another form of middleman company which bills itself as the nation’s first direct access lab testing service with 200 locations. This is Any Lab Test Now’s second consecutive year on the list, according to a news release.

Unlike ixlayer, Any Lab Test Now’s business model features independently owned and operated locations around the US. Customers go online to choose a testing location, pay for tests, and schedule an appointment. Tests include:

At-Home Testing Market Growing

Allied Market Research reported that the global at-home testing market is expected to grow by about 10.5% annually from 2022 to 2031, when it will reach $45.5 billion.

Another middleman company offering at-home tests is Everlywell of Austin, Texas. Other middleman companies that enable consumers to order tests online and then visit a local clinical laboratory for specimen collection include Testing.com and Walk-In-Lab.com.

Ever since the COVID-19 pandemic, demand for at-home sample collection testing has grown steadily. Dark Daily has covered this in numerous ebriefs. That middleman companies are showing up on the Inc. 5000 list of fastest growing companies indicates that the middleman sector of the clinical laboratory testing industry is growing as well.

—Donna Marie Pocius

Related Information:

ixlayer Joins the Inc. 5000 List of Fastest Growing Companies in America

2023 Inc. 5000 List Company Profile: ixlayer

Health Tech Startup ixlayer Partners with CVS on Home Health Tests

ixlayer Enhances At-Home Diagnostic Health Testing Platform with Cutting-Edge AI and Data Visualization

Any Lab Test Now Lands on Prestigious Inc. 5000 for Second Consecutive Year

What’s Next for At-home Diagnostic Testing: Four Trends to Watch in 2024

Allied Market Research: Home Testing Market

Can Consumers Collect Their Own Biological Specimens for Direct-to-Consumer SARS-CoV-2 Tests? FDA Says ‘No’ to Clinical Labs Announcing Such Tests

Following criticism over delays in authorizing medical LDT COVID-19 tests, the FDA swiftly shut down consumer at-home specimen collection schemes

Banning COVID-19 tests that rely on consumers’ collecting their own specimens at home is one example where the federal US Food and Drug Administration (FDA) took remarkably swift action. It’s also interesting to note how some business people—who lack formal training in clinical laboratory medicine—often are ready to seize any opportunity to sell lab tests directly to consumers, regardless of whether such tests are reliable, accurate, medically-necessary, and reasonably priced.

Last month, in the midst of this novel coronavirus pandemic, the attempt by a handful of direct-to-consumer (DTC) lab companies to sell COVID-19 tests to customers was speedily stopped by the FDA less than 10 days after the agency became aware of the DTC testing schemes. This all happened off the radar screen of most pathologists and clinical laboratory administrators, whose full-time attention has been on serving the urgent needs of their parent hospitals, referring physicians, and patients.

Within days of each other, several direct-to-consumer lab testing companies announced plans to offer COVID-19 tests to consumers. A common feature of these offerings was that each DTC company would send a collection kit to the consumer, who would collect his or her specimen at home. The kit would then be sent to one of the DTC company’s CLIA-certified laboratories, where the SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) test would be performed.

Those DTC companies were:

A flurry of press releases and news interviews about how consumers could order and pay for their own COVID-19 test, collect the specimen at home, and have a Clinical Laboratory Improvement Amendments (CLIA)-certified lab perform the test quickly caught the attention of the FDA. Federal officials took immediate action, or close to it.

On March 20, the FDA issued a warning to healthcare consumers to beware of “unauthorized fraudulent COVID-19 test kits.” On the same day, the FDA announced updated guidance on its website pointing to recent policy adjustments stating that “testing by CLIA-certified labs that had not yet acquired Emergency Use Authorization (EUA) for their COVID-19 diagnostic does not apply to at-home COVID-19 testing, ‘including self-collection of samples to be sent to a clinical laboratory,’” reported MobiHealthNews.

“We want to alert the American public that, at this time, the FDA has not authorized any test that is available to purchase for testing yourself at home for COVID-19,” the FDA said in a statement. “The FDA sees the public health value in expanding the availability of COVID-19 testing through safe and accurate tests that may include home collection, and we are actively working with test developers in this space.”

Nevertheless, the FDA stipulated that at-home specimen collection was still not authorized.

Collectively, the FDA’s two actions sent an unmistakable message to the DTC lab companies that affected their consumer COVID-19 testing plans. Following public release of the FDA’s recommendation and policy change, several of the DTC lab companies posted messages on their websites disclosing that they would not be selling COVID-19 tests with consumer self-collection after all.

Everlywell Health’s DTC Clinical Laboratory Test Plan

News stories about the plans of these companies contained details that pathologists and clinical laboratory managers will find interesting. That is certainly true of Everlywell, a DTC lab company with a distinctive background.

Austin-based Everlywell was founded in 2015 by Julia Cheek. She appeared on the Shark Tank television program in 2017 and received $1 million in funding for her business plan, which Dark Daily covered. Cheek’s plan was to sell selected medical laboratory tests directly to consumers, including placing collection kits in retail stores and pharmacies. in the same year, investors pumped another $4 million into Everlywell, for a total of $5 million in venture capital funding, reported Business Wire.

“The extreme shortage of tests for COVID-19 puts millions of Americans at risk,” said Julia Cheek (above), Founder and CEO of Everlywell, in a March 18, 2020, press release. She added, “Everlywell is committed to helping stop the spread of COVID-19 in the US by making this test widely available. As the national leader in at-home lab testing, we want to use our resources and expertise to help as many people as we can. We are committed to this fight, and we’re here to help.” A few days later, the FDA reiterated its ban on at-home COVID-19 specimen collection. (Photo copyright: Forbes/Whitney Martin.)

Everlywell, which manufactures laboratory test kits for everything from general wellness and energy/weight, to men’s health, women’s health, and sexual health, was among several companies that just days before the FDA’s warning had announced plans for an at-home COVID-19 lab test with telehealth diagnosis.

Before the FDA banned at-home testing, Everlywell had an initial supply of 30,000 collection kits and planned to work with “multiple labs to scale infrastructure,” with a goal of testing 250,000 people weekly, stated a company news release. In news interviews, Everlywell said these consumer-collected specimens would be done by CLIA-certified clinical laboratories. However, the company did not name the lab companies it expected to use to perform those tests.

Everlywell’s at-home test carried a $135 price tag for consumers, an amount the company noted was “at-cost.” Before purchasing a COVID-19 test, consumers are required to complete an eligibility questionnaire developed in accordance with CDC recommendations. Testing includes a free telehealth consultation with a board-certified physician for consumers who tested positive.

However, after the FDA issued its March 20 warning, Everlywell announced on its website that its COVID-19 test would not be available for individual purchase.

“Our frontline healthcare workers are in desperate need of testing,” the site states. “We have made the decision to allocate today’s test supply to hospitals and healthcare providers only.”

Everlywell was asked to comment on these matters by Dark Daily’s sister publication, The Dark Report. As of this date, the company has not responded to that request.

Other DTC Companies Suspend Plans to Sell At-Home COVID-19 Test Kits

The Wall Street Journal (WSJ) reported that Scanwell Health, Nurx Inc., and Curative Inc. also were among the handful of companies that curtailed plans to launch at-home COVID-19 testing following the FDA’s announcement.

Scanwell Health now plans to wait for FDA clearance under the EUA for its at-home COVID-19 blood test.

Though the US is making strides to increase testing, lack of testing capacity has hamstrung the nation’s healthcare system as it attempts to control the COVID-19 pandemic.

An at-home test would appear to be one option for increasing COVID-19 testing nationwide. However, the FDA is signaling to these direct-to-consumer lab testing companies—along with clinical laboratories—that specimen quality issues associated with consumers collecting their own samples carry the risk of producing inaccurate test results.

This is something that pathologists and medical laboratory professionals understand because the largest source of errors in clinical laboratory testing come from the pre-analytical stage. This is the part of the testing process where a specimen is collected, then transported to a laboratory and prepared for analysis at the bench.

—Andrea Downing Peck

Related Information:

FDA Says Patients Can Self-Administer Covid-19 Tests, But Not at Home

Coronavirus (COVID-1) Update: FDA Alerts Consumers about Unauthorized Fraudulent COVID-19 Test Kits

The FDA Is Forcing the CDC to Waste Time Double Testing Some Coronavirus Cases

Coronavirus (COVID-19) Update: FDA Issues New Policy to Help Expedite Availability of Diagnostics

Coronavirus (COVID-19) Update: FDA Provides More Regulatory Relief During Outbreak, Continues to Help Expedite Availability of Diagnostics

Everlywell Announces Monday Launch of Solution to Get Tested and Diagnosed for COVID-19 from Home

Startup Aims to Produce 10,000 COVID-19 Kits a Day at Los Angeles Lab

At-Home COVID-19 Testing Services Pump the Brakes After FDA Warns Of ‘Fraudulent’ Kits

Policy for Diagnostic Tests for Coronavirus Disease-2019 during the Public Health Emergency

Why the CDC Botched its Coronavirus Testing

FDA Warns Consumers Against At-Home Coronavirus Tests Kits

FAQs on Diagnostic Testing for SARS-CoV-2

Coronavirus (COVID-19) Update: Daily Roundup

Policy for Diagnostic Tests for Coronavirus Disease-2019 During the Public Health Emergency

Meet the Startup Revolutionizing the Lab Testing Industry

EverlyWell Raises Additional Capital Bringing Total to $5 Million in Funding

Everlywell announces Monday launch of solution to get tested and diagnosed for COVID-19 from home

Direct-to-Consumer Clinical Laboratory Test Developer, EverlyWell, Receives $1 Million in Funding from Shark Tank Investor

Direct-to-Consumer Lab Test Start-Up EverlyWell Puts Clinical Laboratory Tests on Shelves at CVS and Target

If direct-to-consumer testing continues to attract healthcare consumers and financial investors, medical laboratories could have a new source of revenue

Many have tried but few have found the right formula to offer medical laboratory tests directly to consumers. Direct-to-consumer lab testing as a robust business model has been an elusive goal. But now one entrepreneur wants to crack this market and just attracted $50 million in venture capital to fund her idea!

Outsiders often establish industries. This was the case when Jeff Bezos created Amazon in 1994. The online retailer transformed the way books were sold and, subsequently, established a massive new retail market.

Along the same lines, Julia Taylor Cheek, Founder and CEO of EverlyWell, a well-financed digital health company based in Austin—hopes to build a similarly disruptive business in the clinical laboratory industry.

Cheek is increasing her company’s outreach to consumers by putting some of the company’s direct-to-consumer (DTC) medical tests on store shelves at CVS and Target.

A former consultant and Harvard Business School graduate, Cheek raised $50 million in financing to expand EverlyWell’s digital platform. According to a news release, “Just two full years into operation, EverlyWell is reporting 300% year-over-year customer growth and a world-class consumer Net Promoter Score (NPS).”

Sound familiar? Dark Daily reported last year on Cheek’s appearance on Shark Tank, where she secured $1 million from Lori Greiner, one of the television reality show’s participating entrepreneurs. Ever since then, many in the media have compared Cheek to Theranos founder Elizabeth Holmes. It’s a comparison that Cheek does not appreciate.

“I think it’s a representation of sexism in our space. There are 15 other companies that have popped up in blood testing and you don’t hear anyone comparing Theranos to those male-founded startups,” she told Inc.

However, Dark Daily believes Cheek may be missing one basis for the comparison with Elizabeth Holmes. Holmes intended for Theranos to serve consumers with lab testing, and let consumers order and purchase their own medical laboratory tests. Cheek is talking about the same primary business strategy of letting consumers purchase their own lab tests.

Armed with this additional financing from investors, EverlyWell intends to expand services and develop new partnerships with retail pharmacy chain CVS Health (NYSE:CVS) and for-profit insurance company Humana (NYSE:HUM).

The news release notes, “The company has also expanded its product line to offer 35 panels, including first-to-market tests in fertility, vitamins, peri- and post-menopause, and high-risk HPV. In addition, EverlyWell has launched an end-to-end care model for consumers, now offering an independent physician consult and prescription, if appropriate, for select STDs and Lyme Disease testing. All of this is included in an upfront price before purchase.”

EverlyWell Intent on Bringing Medical Laboratory Tests to Retail

Earlier this year, EverlyWell made nine lab tests available in more than 1,600 Target store locations, MedCity News reported. This may suggest that retailers are intrigued with direct-to-consumer lab testing.

“We didn’t create new tests or technologies. Instead, we’ve built technology that empowers people to get tests more easily. Our medical director works with the labs to create panels that are already validated and clinically relevant and understandable for consumers,” Julia Taylor Cheek (above), Founder and CEO of EverlyWell told Forbes. (Photo copyright: Arnold Wells/Austin Business Journal.)

Cheek reportedly established EverlyWell after becoming disenchanted with medical laboratory tests that she felt were not well explained and too costly under high-deductible health plans.

Just two years on, EverlyWell reports “hundreds of thousands of customers and tens of millions in sales.” The company plans to add additional staff on top of its existing 70 employees in anticipation of the new funding, Austin Business Journal reports.

“We are building a consumer brand, which means we have to be where people shop. We need to be in places like CVS and Target to really allow for broader distribution and name recognition,” Cheek told the Austin American-Statesman.

What Draws People to EverlyWell?

EverlyWell offers home health test kits, priced from $49 to $400 that people can order without a doctor’s prescription and pay for online. Users take their samples (saliva, urine, or a pinprick of blood) with provided lancets and cotton swabs, MedCity News reported.

EverlyWell’s top selling tests are:

  • Food sensitivity-$159;
  • Thyroid function-$159;
  • Metabolism-$89; and
  • Vitamin D deficiency-$99.

EverlyWell says it is “first” in direct-to-consumer tests for:

According to VentureBeat:

  • EverlyWell Test kits come with registration information, instructions, collection tools;
  • Biological samples are sent by consumers to CLIA (Clinical Laboratory Improvement Amendments)-certified labs that partner with EverlyWell;
  • Results are generally completed within 10 days depending on type of test and business volume;
  • A physician reviews the test results;
  • Reports on test results are electronically accessible through smartphone apps and online web dashboards.  

“Lab testing is arguably one of the most important steps in preventing and managing illness but has been largely ignored by digital health companies. EverlyWell is successfully navigating an entrenched industry to offer consumers an opportunity to take charge of their own health,” said Eric Kim, Managing Partner at Goodwater Capital (which led the financing), in the news release

“We’re building the definitive technology-enabled healthcare platform that consumers deserve and have already come to expect in other areas of their lives,” Cheek told VentureBeat. “As high-deductible plans become the norm, consumers are becoming discerning buyers who look for seamless, digitally enabled experiences.”

Learning from EverlyWell

Of course, pathologists and medical laboratory professionals will watch to see if EverlyWell can sustain its rapid rise in popularity with healthcare consumers. In particular, those consumers who prefer DTC testing over traditional clinical laboratory visits and who may be on high-deductible health plans.

The DTC test market represents an opportunity that most clinical laboratories have yet to take seriously. There are many reasons why medical lab managers and pathologists would be taking a “wait and see” attitude. Meanwhile, EverlyWell has $50 million of investors’ money to use to demonstrate the financial viability of its strategy to encourage consumers to purchase their own clinical laboratory tests—and even collect their own specimens at home!

—Donna Marie Pocius

Related Information:

EverlyWell raises $50 Million in Funding to Accelerate Digitally Enabled Consumer Lab Testing Platform

This Entrepreneur Wants to Change How You Get Blood Tests (and Make You Forget About Theranos)

Direct-to-Consumer Lab Testing Start-up EverlyWell Raises $50 Million

How This Female Founder is Democratizing the Healthcare Industry

EverlyWell $50 Million Funding to Put Test Kits in More Stores

Austin Health Tech Firm EverlyWell Lands $50 Million for Expansion

EverlyWell Raises $50 Million for At-Home Medical Tests

Direct-to-consumer Clinical Laboratory Test Developer EverlyWell Receives $1 Million in Funding from Shark Tank Investor

Innovations in Microsampling Blood Technology Mean More Patients Can Have Blood Tests at Home and Clinical Laboratories May Advance Toward Precision Medicine Goals

Direct-to-Consumer Clinical Laboratory Test Developer, EverlyWell, Receives $1 Million in Funding from Shark Tank Investor

Direct-to-consumer medical laboratory testing company gets a major shot in the arm as developers find ready investors and increasing consumer demand

Clinical laboratory tests, usually performed without fanfare, were thrust into the limelight during a recent episode of Shark Tank, an American reality TV show on which aspiring entrepreneurs compete for the attention and partnership funds of various investors.

EverlyWell, a direct-to-consumer (DTC) company that offers at-home lab tests without lab visits or doctor referrals, obtained a $1-million line of credit from Lori Greiner, one of Shark Tank’s participating entrepreneurs, according to MobiHealthNews. EverlyWell has consumers collect their own specimens at home, which are then sent to a medical laboratory testing facility.

Based in Austin, Texas, EverlyWell was founded in 2015 by Julia Taylor Cheek, CEO, with an aim to “make lab tests accessible, simple, and meaningful,” according to a news release. Cheek is also a Venture Partner with NextGen Venture Partners and formerly the Director of Strategy and Operations with the George W. Bush Institute.

“It’s incredible for the industry that we were selected and aired on a show like Shark Tank. It really shows the intersection of what’s happening in consumer healthcare and the high cost in healthcare and that people are really responding to new solutions,” Cheek told MobiHealthNews.

“I think the product is brilliantly crafted,” Greiner stated during the episode’s taping, according to MobiHealthNews. “It’s really nice; it’s really easy. It’s super clear. I think the state of healthcare in our country now is so precarious. I think this gives people an empowered way … to know whether or not they have to go find a doctor,” she concluded.

Greiner offered the $1 million line of credit (with 8% interest) in exchange for a 5% equity stake in EverlyWell, explained Austin360. According to SiliconHillsNews, she did so after reviewing certain EverlyWell financial indicators, including:

  • $2.5 million in revenue in 2016;
  • $5 million expected revenue in 2017; and
  • 20% monthly growth rate.

Julia Cheek, CEO and Founder of EverlyWell (above), in a news release following her success on reality show Shark Tank, said, “We’re leading a major shift in the consumer health marketplace by bringing the lab to consumers’ doorsteps, and we are moving quickly to expand our channels, launch innovative tests, and deliver a world-class customer experience.” (Photo copyright: Forbes/Whitney Martin.)

Physician Review Still Part of Home-testing Process

EverlyWell lists 22 home lab tests on its website and a market share that encompasses 46 states. Shoppers can search for specific tests based on symptoms or by test categories that include:

  • General Wellness;
  • Men’s Health;
  • Women’s Health;
  • Energy and Weight; and
  • Genomic Test (through a partnership with Helix, a personal genomics company).

The most popular test panels include:

  • Food sensitivity;
  • Thyroid;
  • Metabolism;
  • Vitamin D; and,
  • Inflammation.

Prices range from $59 for a glycated hemoglobin (HbA1c) test (found under the general wellness category) to $399 for a women’s health testing kit. EverlyWell explains that it has no insurance contracts for these diagnostic tests, which do not require office or lab visits.

The testing process, according to EverlyWell’s website, proceeds as follows:

  • After ordering and paying online, kits arrive at the customer’s home;
  • The consumer self-collects a sample (such as blood spots, dried urine, or saliva) and returns it by prepaid mail to a medical laboratory that partners with EverlyWell. The company notes that it works with CLIA (Clinical Laboratory Improvement Amendment)-certified laboratories;
  • A board-certified doctor reviews the lab results; and,
  • A report is available online in a few days.

“Our goal is not to remove the importance of physician review. It’s to make the experience easier for the consumer,” Cheek told Texas CEO Magazine. “We designed a platform that is all about access and empowering consumers to have access to and monitor their own health information,” she continued.

Texas CEO Magazine explained that Cheek was inspired to create the company following “a bad personal experience with health and wellness testing that sent her to seven different specialists, cost $2,000 out of pocket, and left her with pages of unreadable results.”

Since then, the three-year old start-up company has garnered more than $5 million in venture capital, noted the news release.

Many Choices in Direct-to-Consumer Lab Company Market

EverlyWell is not the only player in the DTC clinical laboratory test space. According to MedCityNews, there are at least 20 other DTC lab test companies in the market including:

  • 23andMe;
  • Laboratory Corporation of America (LabCorp);
  • Mapmygenome;
  • Pathway Genomics;
  • Quest Diagnostics (Quest);
  • Sonora Quest Labs;
  • Theranos; and others.

The direct-to-consumer lab test market grew from $15 million to about $150 million in 2015 and includes both large and small clinical laboratory test developers, noted Kalorama Information.

Clearly, the DTC testing market is expanding and garnering the attention of major developers and investors alike. This growing demand for home-testing diagnostics could impact anatomic pathology groups and smaller clinical laboratories in the form of reduced order testing and decreased revenue.

—Donna Marie Pocius

Related Information:

Mail-Order Lab Test Startup EverlyWell Makes Million Dollar Deal on ABC’s Shark Tank

EverlyWell Raises Additional Capital, Bringing Total to $5 Million

This Austin Entrepreneur Scored Historic Deal on Shark Tank

Austin-based EverlyWell Lands Deal on Shark Tank

Innovative Texas Businesses: Empowering Consumers; Julia Cheek’s EverlyWell’s Health and Wellness Testing

Meet the Start-up Revolutionizing the Lab Testing Industry

20 Key Payers in the Direct-to-Consumer Lab Testing Market

Direct-to-Consumer Services Put Down Roots in US Lab Testing Market

Clinical Pathology Laboratories Should Expect More Direct-to-Consumer Testing

Sales of Direct-to-Consumer Clinical Laboratory Genetic Tests Soar, as Members of Congress Debate How Patient Data Should be Handled, Secured, and Kept Private

;